Web of Science

Permanent URI for this collectionhttps://hdl.handle.net/11452/19318

Browse

Now showing 1 - 3 of 3

Extrapulmonary involvement in patients with sarcoidosis in Turkey
(Wiley, 2011-04) Okumuş, Gülfer; Musellim, Benan; Çetinkaya, Erdoğan; Türker, Hatice; Uzun, Oğuz; Sağlam, Leyla; Kumbasar, Özlem Özdemir; Çelik, Gökhan; Annakkaya, Ali Nihat; Altıay, Gündeniz; Tabak, Levent; Sakar, Ayşin; Kiter, Göksel; Erturan, Serdar; Türktaş, Haluk; Yalnız, Enver; Akkoçlu, Atilla; Ogus, Candan; Doğan, Ömer Tamer; Özkan, Metin; Aktoğu, Serir; Uzel, Işıl; Öngen, Gül; Uzaslan, Esra Kunt; Tıp Fakültesi; Akciğer Hastalıkları Ana Bilim Dalı; 8761653500
Background and objective: Extrapulmonary sarcoidosis is common, and is almost always associated with concomitant thoracic involvement. Extrapulmonary manifestations vary on the basis of gender, age at presentation and ethnicity. The aim of this study was to investigate extrapulmonary involvement in patients with sarcoidosis in Turkey. Methods: This study was conducted by Turkish Thoracic Society Clinical Problems Study Group. New cases of sarcoidosis between 1 June 2004 and 31 May 2006 were recorded on electronic case record forms sent to all potential investigators and information about extrapulmonary involvement was collected. Results: One hundred and nineteen of 293 patients (83 female, 36 male, mean age = 45 +/- 12 years) had extrapulmonary involvement in this study (40.6%). The median time to diagnosis was 6 months and this was longer than patients with just thoracic sarcoidosis (P = 0.001). Extrapulmonary symptoms were present in 181 (61.8%) patients, and skin lesions, arthralgia and back pain were the commonest (33.4%, 20.8% and 16.4%, respectively). Incidence of organ involvement was independent of age with the exception of ocular involvement, which was higher in those under the age of 40 years (P = 0.007). Conclusions: Skin and peripheral lymph node involvement were the most common sites of extrapulmonary involvement and ocular involvement was more common in those under the age of 40 years in patients with sarcoidosis in a Turkish population.
Learning platform for smoking cessation project: From begining to date
(European Respiratory, 2012-09-01) Kılınç, Oğuz; Akçay, Şule; Bostan, Pınar Pazarlı; Elbek, Osman; Aytemur, Zeynep; Özge, Cengiz; Öztuna, Funda; Sağlam, Leyla; Uysal, Atilla; Örsel, Osman; Dilektaşlı, Aslı Görek; Uzaslan, Esra Kun; Tıp Fakültesi; Akciğer Hastalıkları Ana Bilim Dalı; AAI-1004-2021
Although 35% of the adults in Turkey are current smokers, the number of trained physicians and smoking cessation (SC) clinics are not enough to meet the demand. Aim: This national project aimed to create the necessary infrastructure for providing SC therapy all-around the country and to train physicians in this topic. This project was run by Turkish Thoracic Society Tobacco Working Group and supported by a grant from Pfizer Foundation. Methods: For this purpose, an organization network including field training teams was planned. The training materials were prepared and standardized. A website of the project including a wide e-learning platform was created (www.sigarabirakmadaogrenmezemini.org). Results: Firstly, a central training program was planned. Forty volunteers from all regions of Turkey were participated to this program. Afterwards, field training programs were started to perform by these trainers. From the beginning field training sessions were performed in 11 cities with more than 300 participants. The project website was visited by 10.369 visitors and 518 participants completed e-training module since April 2011. Conclusion: The SÖZ project enabled a training ground that will last for years; a professional website and a trainer staff to generalize the program. Through this project, the integration of SC intervention in all health service steps will be provided, the number of SC clinics in Turkey will increase, and in future smoking rate will reduce in our country.
Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization
(Dove Medical, 2017) Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdoğen; Uzaslan, Esra; Budak, Ferah; Coşkun, Funda; Ursavaş, Ahmet; Ercan, İlker; Ege, Ercüment; Tıp Fakültesi; Akciğer Hastalıkları Ana Bilim Dalı; 0000-0003-3604-8826; AAD-1271-2019; F-4657-2014; AAI-3169-2021; AAI-1004-2021; ABF-2367-2020; 36466376600; 57189524206; 8761653500; 6701913697; 21734137500; 8329319900; 6603789069; 6701341320
Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. Materials and methods: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. Results: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P, 0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P, 0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. Conclusion: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores.

Browse

Browsing by Department "Akciğer Hastalıkları Ana Bilim Dalı"